Advanced search×

"Inverse benefit law" explains how drug marketing undermines patient safety.

Janice Hopkins Tanne

BMJ 342(7792):d598 (2011) PMID 21278216

DOI: 10.1136/bmj.d598
Version: za2963e q8zae q8zb1 q8zcc q8zd9 q8ze4 q8zf4 q8zg3

Similar articles you may find interesting…

  1. Essential care after an inpatient fall: summary of a safety report from the National Patient Safety Agency.
    Frances Healey, Adam Darowski, ... Martin Wiese

    BMJ (2011) PMID 21278215

  2. Frequency and reasons for outcome reporting bias in clinical trials: interviews with trialists.
    R M D RM Smyth, J J JJ Kirkham, ... P R PR Williamson

    BMJ (2011) PMID 21212122

    To provide information on the frequency and reasons for outcome reporting bias in clinical trials. Trial protocols were compared with subsequent publication(s) to identify any discrepancies in the outcomes reported, and telephone interviews were conducted with the res...
  3. Leopold Goldman
    Anne Lyons

    BMJ 342(7790) (2011)